Zastaprazan

Korea's P-CAB push in China is a reimbursement story, not an approval count

K-CAB added 402 Chinese hospitals in the first half and grew sales more than 30%. What holds its second place is NRDL coverage and a patent that outlasts Takeda's by 64 months.